Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …

Despite significant advances in treatment strategies targeting the underlying defect in cystic
fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part …

Introduction: Inhaled antibiotics are probably the safest and most effective therapy for
Pseudomonas aeruginosa chronic lung infection in cystic fibrosis (CF) patients. Areas …

Abstract Purpose In Europe, 4 inhaled antibiotics (tobramycin, colistimethate sodium,
aztreonam, and levofloxacin) are currently approved for the treatment of chronic …

This comprehensive State of the Art review summarizes the current published knowledge
base regarding the pathophysiology and microbiology of pulmonary disease in cystic …

Background Inhaled antibiotics are commonly used to treat persistent airway infection with
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …

Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to
advancements in antimicrobial treatments. New aerosolized antibiotic formulations have …

Patients with cystic fibrosis (CF) are repeatedly exposed to antibiotics, especially during the
pulmonary exacerbations of the disease. However, the available therapeutic strategies are …

Introduction Dosing of antibiotics in people with cystic fibrosis (CF) is challenging, due to
altered pharmacokinetics, difficulty of lung tissue penetration, and increasing presence of …